Free Trial
Your $100 Credit Expires Tomorrow! Get MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion

Inhibrx Biosciences (INBX) Financials

Inhibrx Biosciences logo
$101.32 -9.25 (-8.37%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$102.92 +1.60 (+1.58%)
As of 05/22/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Inhibrx Biosciences

Annual Income Statements for Inhibrx Biosciences

This table shows Inhibrx Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -241 1,688 -140
Consolidated Net Income / (Loss)		 -241 1,688 -140
Net Income / (Loss) Continuing Operations		 -241 1,688 -140
Total Pre-Tax Income 		-240 1,688 -140
Total Operating Income		 -219 -331 -135
Total Gross Profit		 1.80 0.20 1.30
Total Revenue		 1.80 0.20 1.30
Operating Revenue		 1.80 0.20 1.30
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 221 332 136
Selling, General & Admin Expense		 29 128 23
Research & Development Expense		 192 204 113
Total Other Income / (Expense), net		 -21 2,019 -5.03
Interest Expense		 32 13 12
Interest & Investment Income		 12 11 7.55
Other Income / (Expense), net		 -0.58 2,022 -0.38
Income Tax Expense		 0.00 0.00 0.00
Basic Earnings per Share		 ($20.48) $114.01 ($9.04)
Weighted Average Basic Shares Outstanding		 11.78M 14.80M 15.49M
Diluted Earnings per Share		 ($20.48) $112.62 ($9.04)
Weighted Average Diluted Shares Outstanding		 11.78M 14.98M 15.49M
Weighted Average Basic & Diluted Shares Outstanding		 - 14.48M 14.61M

Quarterly Income Statements for Inhibrx Biosciences

This table shows Inhibrx Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -47 -52 -79 1,858 -44 -48 -43 -29 -35 -33 -33
Consolidated Net Income / (Loss)		 -47 -52 -79 1,858 -44 -48 -43 -29 -35 -33 -33
Net Income / (Loss) Continuing Operations		 -47 -52 -79 1,858 -44 -48 -43 -29 -35 -33 -33
Total Pre-Tax Income 		-47 -52 -79 1,858 -44 -48 -43 -29 -35 -33 -33
Total Operating Income		 -41 -46 -74 -161 -47 -50 -43 -27 -34 -31 -31
Total Gross Profit		 0.03 0.12 0.00 0.10 0.00 0.10 0.00 1.30 0.00 - 0.00
Total Revenue		 0.03 0.12 0.00 0.10 0.00 0.10 0.00 1.30 0.00 - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 41 46 74 161 47 50 43 29 34 31 31
Selling, General & Admin Expense		 7.26 7.89 9.97 93 7.90 17 6.02 6.42 5.28 5.57 5.71
Research & Development Expense		 34 38 64 68 39 33 37 22 29 25 25
Total Other Income / (Expense), net		 -5.71 -5.96 -4.89 2,019 2.93 2.06 -0.41 -1.26 -1.44 -1.91 -2.51
Interest Expense		 7.91 8.15 8.13 5.36 0.00 - 2.69 3.14 3.18 3.19 3.51
Interest & Investment Income		 2.41 2.32 3.30 2.74 2.89 2.00 2.33 2.12 1.78 1.31 1.01
Other Income / (Expense), net		 -0.22 -0.14 -0.06 2,022 0.04 0.06 -0.05 -0.25 -0.05 -0.04 -0.01
Income Tax Expense		 0.01 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($4.31) ($4.39) ($5.77) $127.10 ($2.84) ($4.48) ($2.80) ($1.85) ($2.28) ($2.11) ($2.15)
Weighted Average Basic Shares Outstanding		 10.91M 11.79M 13.64M 14.62M 15.47M 14.80M 15.47M 15.47M 15.48M 15.49M 15.59M
Diluted Earnings per Share		 ($4.31) ($4.39) ($5.77) $125.48 ($2.84) ($4.25) ($2.80) ($1.85) ($2.28) ($2.11) ($2.15)
Weighted Average Diluted Shares Outstanding		 10.91M 11.79M 13.64M 14.81M 15.47M 14.98M 15.47M 15.47M 15.48M 15.49M 15.59M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 14.48M 14.48M 14.48M 14.48M 14.49M 14.54M 14.61M 14.67M

Annual Cash Flow Statements for Inhibrx Biosciences

This table details how cash moves in and out of Inhibrx Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.06 -125 -28
Net Cash From Operating Activities		 -193 -194 -130
Net Cash From Continuing Operating Activities		 -193 -194 -130
Net Income / (Loss) Continuing Operations		 -241 1,688 -140
Consolidated Net Income / (Loss)		 -241 1,688 -140
Depreciation Expense		 1.19 2.29 2.48
Amortization Expense		 4.90 2.07 2.44
Non-Cash Adjustments To Reconcile Net Income		 25 -1,940 11
Changes in Operating Assets and Liabilities, net		 17 53 -6.02
Net Cash From Investing Activities		 -4.59 -2.60 -0.03
Net Cash From Continuing Investing Activities		 -4.59 -2.60 -0.03
Purchase of Property, Plant & Equipment		 -4.59 -2.60 -0.03
Sale of Property, Plant & Equipment		 - 0.00 0.00
Net Cash From Financing Activities		 202 72 101
Net Cash From Continuing Financing Activities		 202 72 101
Repayment of Debt		 - 0.00 -0.13
Issuance of Debt		 - 0.00 100
Other Financing Activities, net		 2.32 72 1.61
Cash Interest Paid		 27 12 8.90
Cash Income Taxes Paid		 0.00 0.00 0.00

Quarterly Cash Flow Statements for Inhibrx Biosciences

This table details how cash moves in and out of Inhibrx Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 145 -59 -25 -26 -31 -44 64 -30 -33 -29 37
Net Cash From Operating Activities		 -54 -57 -63 -57 -30 -44 -36 -30 -34 -30 -38
Net Cash From Continuing Operating Activities		 -54 -57 -63 -57 -30 -44 -36 -30 -34 -30 -38
Net Income / (Loss) Continuing Operations		 -52 -94 -79 1,858 -44 -48 -43 -29 -35 -33 -33
Consolidated Net Income / (Loss)		 -52 -94 -79 1,858 -44 -48 -43 -29 -35 -33 -33
Depreciation Expense		 0.30 0.30 0.36 0.48 0.76 0.69 0.68 0.66 0.58 0.56 0.54
Amortization Expense		 1.24 1.25 1.24 0.82 - - 0.53 0.63 0.64 0.64 0.73
Non-Cash Adjustments To Reconcile Net Income		 6.50 6.40 6.37 -1,952 3.46 3.38 2.71 2.85 4.17 1.63 3.14
Changes in Operating Assets and Liabilities, net		 -11 29 7.69 35 9.36 0.07 3.50 -5.43 -3.96 -0.12 -8.99
Net Cash From Investing Activities		 -0.81 -3.44 -1.12 -1.22 -0.25 -0.02 -0.02 - -0.01 - 0.00
Net Cash From Continuing Investing Activities		 -0.81 -3.44 -1.12 -1.22 -0.25 -0.02 -0.02 - -0.01 - 0.00
Purchase of Property, Plant & Equipment		 -0.81 -3.44 -1.12 -1.22 -0.25 -0.02 -0.02 - -0.01 - 0.00
Net Cash From Financing Activities		 200 0.86 39 33 - - 100 - 0.35 1.25 75
Net Cash From Continuing Financing Activities		 200 0.86 39 33 - - 100 - 0.35 1.25 75
Repayment of Debt		 - - 0.00 - - - -0.13 - - - 0.00
Issuance of Debt		 - - 0.00 - - - 100 - - - 75
Other Financing Activities, net		 0.02 1.09 39 33 - - 0.00 - 0.35 1.25 0.47
Cash Interest Paid		 - - 6.89 4.61 - - 1.30 2.54 2.54 2.51 2.78
Cash Income Taxes Paid		 - - 0.00 0.00 - - 0.00 0.00 - - 0.00

Annual Balance Sheets for Inhibrx Biosciences

This table presents Inhibrx Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 308 181 146
Total Current Assets		 295 160 133
Cash & Equivalents		 278 153 124
Accounts Receivable		 0.78 0.42 0.18
Prepaid Expenses		 17 7.38 8.44
Plant, Property, & Equipment, net		 6.42 6.20 3.73
Total Noncurrent Assets		 6.12 14 9.91
Other Noncurrent Operating Assets		 6.12 14 9.91
Total Liabilities & Shareholders' Equity		 308 181 146
Total Liabilities		 264 47 138
Total Current Liabilities		 56 41 34
Accounts Payable		 11 9.25 5.94
Accrued Expenses		 43 30 26
Other Current Liabilities		 2.06 1.60 2.33
Total Noncurrent Liabilities		 208 6.45 105
Long-Term Debt		 207 0.00 101
Other Noncurrent Operating Liabilities		 1.11 6.45 4.13
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 44 134 7.99
Total Preferred & Common Equity		 44 134 7.99
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 44 134 7.99
Common Stock		 657 240 254
Retained Earnings		 -614 -106 -246

Quarterly Balance Sheets for Inhibrx Biosciences

This table presents Inhibrx Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 258 223 243 212 177 184
Total Current Assets		 242 207 223 194 161 171
Cash & Equivalents		 227 196 217 187 153 162
Accounts Receivable		 1.39 1.13 0.21 0.97 0.84 0.19
Prepaid Expenses		 14 9.99 6.65 6.43 7.50 9.50
Plant, Property, & Equipment, net		 7.61 6.88 5.55 4.89 4.31 3.20
Total Noncurrent Assets		 8.76 8.24 14 13 12 9.43
Other Noncurrent Operating Assets		 8.76 8.24 14 13 12 9.43
Total Liabilities & Shareholders' Equity		 258 223 243 212 177 184
Total Liabilities		 39 44 148 144 141 205
Total Current Liabilities		 39 44 44 39 36 27
Accounts Payable		 13 12 8.89 8.29 6.77 8.76
Accrued Expenses		 24 30 33 28 27 15
Other Current Liabilities		 2.17 1.84 1.97 2.17 2.25 2.41
Total Noncurrent Liabilities		 0.00 0.00 105 105 105 178
Long-Term Debt		 0.00 0.00 99 99 100 175
Other Noncurrent Operating Liabilities		 0.00 0.00 5.90 5.34 4.74 3.50
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 219 178 94 69 37 -21
Total Preferred & Common Equity		 219 178 94 69 37 -21
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 219 178 94 69 37 -21
Common Stock		 234 237 244 247 250 259
Retained Earnings		 -14 -58 -149 -178 -213 -280

Annual Metrics And Ratios for Inhibrx Biosciences

This table displays calculated financial ratios and metrics derived from Inhibrx Biosciences' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - 14,543,738.00
DEI Adjusted Shares Outstanding		 - - 14,543,738.00
DEI Earnings Per Adjusted Shares Outstanding		 - - -9.63
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -153 -331 -95
Return On Investment Capital (ROIC_SIMPLE)		 -61.27% -248.12% -87.07%
Earnings before Interest and Taxes (EBIT)		 -220 1,690 -135
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -214 1,694 -130
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -340 -98
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 -27 -19 -16
Increase / (Decrease) in Invested Capital		 0.00 8.44 3.34
Book Value per Share		 $3.69 $9.23 $0.55
Tangible Book Value per Share		 $3.69 $9.23 $0.55
Total Capital		 250 134 109
Total Debt		 207 0.00 101
Total Long-Term Debt		 207 0.00 101
Net Debt		 -71 -153 -24
Capital Expenditures (CapEx)		 4.59 2.60 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -39 -33 -25
Debt-free Net Working Capital (DFNWC)		 239 120 99
Net Working Capital (NWC)		 239 120 99
Net Nonoperating Expense (NNE)		 88 -2,019 46
Net Nonoperating Obligations (NNO)		 -71 -153 -24
Total Depreciation and Amortization (D&A)		 6.09 4.35 4.92
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $114.01 ($9.04)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 14.80M 15.49M
Adjusted Diluted Earnings per Share		 $0.00 $112.62 ($9.04)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 14.98M 15.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.48M 14.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -153 -331 -95
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Inhibrx Biosciences

This table displays calculated financial ratios and metrics derived from Inhibrx Biosciences' official financial filings.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - 14,475,904.00 - - - 14,543,738.00 14,607,036.00
DEI Adjusted Shares Outstanding		 - - - - - 14,475,904.00 - - - 14,543,738.00 14,607,036.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -3.31 - - - -2.26 -2.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 233.33% -100.00% - 0.00% 1,200.00% 0.00% - 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% 4,580.54% -3.55% - 42.25% -101.42% 29.04% - 28.92%
EBIT Growth		 0.00% 0.00% 0.00% 4,577.41% -1.73% - 41.87% -101.49% 27.59% - 27.97%
NOPAT Growth		 0.00% 0.00% 0.00% -456.02% -2.12% - 41.89% 88.08% 27.75% - 27.91%
Net Income Growth		 0.00% 0.00% 0.00% 4,048.85% 15.30% - 44.97% -101.54% 19.62% - 22.79%
EPS Growth		 0.00% 0.00% 0.00% 3,011.37% 35.31% - 51.47% -101.47% 19.72% - 23.21%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% 44.18% - 43.07% 47.78% -11.70% - -5.94%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 94.83% -69.16% - -465.71%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% -149.92% 8.53% - 67.14%
Revenue Q/Q Growth		 0.00% 296.67% 0.00% 0.00% -100.00% - 0.00% 0.00% -100.00% - 0.00%
EBITDA Q/Q Growth		 0.00% -6.89% 0.00% 2,675.93% -102.47% - 0.00% 36.88% -23.87% - 0.29%
EBIT Q/Q Growth		 0.00% -10.60% 0.00% 2,618.32% -102.51% - 0.00% 35.66% -22.52% - 0.07%
NOPAT Q/Q Growth		 0.00% -10.86% 0.00% -211.35% 79.64% - 0.00% 36.16% -23.45% - -0.01%
Net Income Q/Q Growth		 0.00% -10.07% 0.00% 2,460.58% -102.36% - 0.00% 33.84% -23.04% - -1.85%
EPS Q/Q Growth		 0.00% -1.86% 0.00% 2,274.70% -102.26% - 0.00% 33.93% -23.24% - -1.90%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -10.96% 9.03% 47.21% - 17.90% 16.55% -12.92% - -26.24%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 90.29% - 0.00% -20.14% -217.39% - -49.56%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -138.39% - 0.00% 20.04% 12.75% - 50.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 100.00% 0.00% - 0.00% 100.00% 0.00% - 0.00%
EBITDA Margin		 -138,520.00% -37,326.89% 0.00% 1,861,932.00% 0.00% - 0.00% -2,026.77% 0.00% - 0.00%
Operating Margin		 -137,796.67% -38,510.08% 0.00% -160,898.00% 0.00% - 0.00% -2,106.85% 0.00% - 0.00%
EBIT Margin		 -138,520.00% -38,623.53% 0.00% 1,860,633.00% 0.00% - 0.00% -2,125.77% 0.00% - 0.00%
Profit (Net Income) Margin		 -156,840.00% -43,520.17% 0.00% 1,858,011.00% 0.00% - 0.00% -2,204.15% 0.00% - 0.00%
Tax Burden Percent		 100.01% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.01% 100.00% - 100.00%
Interest Burden Percent		 113.21% 112.67% 106.53% 99.86% 93.81% - 100.84% 103.68% 104.13% - 108.09%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% 0.00% - 1,824.35% -113.71% -144.07% - -354.69%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% -12.65% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% -13.12% 0.00% - 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% 0.00% - 1,824.35% -113.71% -144.07% - -354.69%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% - 1,824.35% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -29 -32 -52 -161 -33 -35 -30 -19 -24 -22 -22
NOPAT Margin		 -96,457.67% -26,957.06% 0.00% -160,897.83% 0.00% - 0.00% -1,474.79% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 1,779.87% -11.31% - -22.53% -6.04% -9.29% - -22.56%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -73.35% -18.36% -26.16% -15.55% -11.42% -17.31% -19.94% -14.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 24,210.00% 6,629.41% 0.00% 93,366.00% 0.00% - 0.00% 494.00% 0.00% - 0.00%
R&D to Revenue		 113,686.67% 31,980.67% 0.00% 67,632.00% 0.00% - 0.00% 1,712.85% 0.00% - 0.00%
Operating Expenses to Revenue		 137,896.67% 38,610.08% 0.00% 160,998.00% 0.00% - 0.00% 2,206.85% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -42 -46 -74 1,861 -47 -50 -43 -28 -34 -31 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -44 -72 1,862 -46 -49 -42 -26 -33 -30 -30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 1.27 - 2.14 3.01 13.25 - 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 1.27 - 2.14 3.01 13.25 - 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 - 1,012.59 147.55 348.48 - 755.41
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 - 0.12 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% - 850.77% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 - 423.25 85.20 310.50 - 765.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 - 0.05 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 - 0.05 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 - 1.04 1.45 2.71 - -8.32
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 - 1.04 1.45 2.71 - -8.32
Financial Leverage		 0.00 0.00 0.00 -1.03 -1.10 - -1.25 -1.09 -1.16 - -1.42
Leverage Ratio		 0.00 0.00 0.00 1.18 1.25 - 2.57 1.63 1.86 - 5.81
Compound Leverage Factor		 0.00 0.00 0.00 1.18 1.17 - 2.59 1.69 1.93 - 6.28
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% - 51.09% 59.15% 73.07% - 113.66%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% - 51.09% 59.15% 73.07% - 113.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% - 48.91% 40.85% 26.93% - -13.66%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 - 0.06 -0.61 -0.67 - -1.48
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 - -0.07 0.53 0.35 - -0.11
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 - 0.06 -0.61 -0.67 - -1.48
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 - -0.33 -0.85 -0.93 - -2.03
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 - 0.39 0.75 0.49 - -0.15
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 - -0.33 -0.85 -0.93 - -2.03
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 - 0.26 0.14 0.62 - 1.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 6.20 4.70 - 5.12 4.98 4.49 - 6.46
Quick Ratio		 0.00 0.00 0.00 5.84 4.48 - 4.97 4.82 4.28 - 6.10
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -153 -15 0.00 -6.61 -7.94 -25 -25 -37
Operating Cash Flow to CapEx		 0.00% -6,688.66% -5,634.50% -4,720.82% -12,259.51% - -170,928.57% 0.00% -338,240.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -28.61 0.00 - -2.46 -2.53 -7.92 - -10.65
Operating Cash Flow to Interest Expense		 0.00 -6.66 -7.76 -10.70 0.00 - -13.35 -9.54 -10.63 - -10.84
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -6.76 -7.89 -10.93 0.00 - -13.36 -9.54 -10.64 - -10.84
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.01 0.01 - 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 - 0.93 1.19 1.43 - 6.50
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 - 0.04 0.22 0.25 - 0.30
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 - 390.55 306.86 256.02 - 56.15
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 - 390.55 306.86 256.02 - 56.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -7.49 -18 -19 -23 -19 -16 -16 -7.70
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 - -0.02 -0.11 -0.08 - -0.08
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -7.49 -18 0.00 -23 -11 1.52 3.34 16
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 30 - 85 119 435 - 995
Market Capitalization		 0.00 0.00 0.00 0.00 227 - 203 207 488 - 982
Book Value per Share		 $0.00 $0.00 $0.00 $15.01 $12.33 $9.23 $6.52 $4.74 $2.54 $0.55 ($1.44)
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $15.01 $12.33 $9.23 $6.52 $4.74 $2.54 $0.55 ($1.44)
Total Capital		 0.00 0.00 0.00 219 178 134 193 168 137 109 154
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 99 99 100 101 175
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 99 99 100 101 175
Net Debt		 0.00 0.00 0.00 -227 -196 -153 -118 -87 -53 -24 13
Capital Expenditures (CapEx)		 0.00 0.81 1.12 1.22 0.25 0.02 0.02 0.00 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -24 -33 -33 -37 -32 -28 -25 -17
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 203 163 120 180 155 125 99 145
Net Working Capital (NWC)		 0.00 0.00 0.00 203 163 120 180 155 125 99 145
Net Nonoperating Expense (NNE)		 18 20 27 -2,019 11 13 13 9.48 12 11 12
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -227 -196 -153 -118 -87 -53 -24 13
Total Depreciation and Amortization (D&A)		 0.00 1.54 1.60 1.30 0.76 0.69 1.21 1.29 1.22 1.21 1.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% - -18,386.50% -2,253.00% -1,974.86% - -1,294.46%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% - 89,873.50% 11,073.21% 8,960.00% - 11,140.69%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% - 89,873.50% 11,073.21% 8,960.00% - 11,140.69%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $127.10 ($2.84) ($4.48) ($2.80) ($1.85) ($2.28) ($2.11) ($2.15)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 14.62M 15.47M 14.80M 15.47M 15.47M 15.48M 15.49M 15.59M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $125.48 ($2.84) ($4.25) ($2.80) ($1.85) ($2.28) ($2.11) ($2.15)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 14.81M 15.47M 14.98M 15.47M 15.47M 15.48M 15.49M 15.59M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 14.48M 14.48M 14.48M 14.48M 14.49M 14.54M 14.61M 14.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -29 -32 -52 -161 -33 -35 -30 -19 -24 -22 -22
Normalized NOPAT Margin		 -96,457.67% -26,957.06% 0.00% -160,897.83% 0.00% - 0.00% -1,474.79% 0.00% - 0.00%
Pre Tax Income Margin		 -156,823.33% -43,518.49% 0.00% 1,858,013.00% 0.00% - 0.00% -2,204.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.26 -5.64 -9.09 347.07 0.00 - -15.97 -8.80 -10.64 - -8.82
NOPAT to Interest Expense		 -3.66 -3.94 -6.36 -30.01 0.00 - -11.17 -6.10 -7.44 - -6.17
EBIT Less CapEx to Interest Expense		 0.00 -5.74 -9.23 346.84 0.00 - -15.98 -8.80 -10.65 - -8.82
NOPAT Less CapEx to Interest Expense		 0.00 -4.04 -6.49 -30.24 0.00 - -11.18 -6.10 -7.44 - -6.17
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Inhibrx Biosciences (INBX) shows a pattern common to early-stage biotech: minimal quarterly revenue paired with persistent net losses, funding primarily through financing activities, and a sizable cash cushion that supports ongoing R&D. Over the four-year window in the data, cash burn from operations has been notable, but liquidity has been repeatedly bolstered by debt and other financing activities. R&D remains the largest ongoing expense, while the company has maintained a multi-quarter runway thanks to sizable cash on hand and new financing in 2025.

  • Large financing inflows in 2025: Net Cash From Continuing Financing Activities around $99.84 million in both Q1 2025 and Q2 2025, helping preserve liquidity (approximately $99.84M in each quarter).
  • Debt issuance in 2025: Issuance of Debt in Q2 2025 of about $99.97 million, boosting available liquidity to support operations and ongoing R&D.
  • Operating cash flow shows stabilization around the lower end of the mid-30s to low-30s per quarter in 2025: Net Cash From Continuing Operating Activities around -$29.95 million (Q2 2025), -$33.82 million (Q3 2025), and -$30.12 million (Q4 2025).
  • Cash on hand remains substantial across the period, with cash and equivalents generally in the low- to mid-range of hundreds of millions (e.g., ~$216.5M in Q1 2025, ~$186.6M in Q2 2025, ~$153.1M in Q3 2025).
  • Revenue remains minimal or zero in the latest quarters, with Q4 2025 revenue reported at $0 and Q3 2025 revenue at $0, indicating limited near-term topline growth.
  • R&D expense remains a dominant cost driver in 2025 (e.g., $25.3M in Q4 2025, $28.5M in Q3 2025, $22.3M in Q2 2025, $36.9M in Q1 2025), underscoring ongoing investment in pipeline but contributing to ongoing losses.
  • Total equity has trended lower through 2025, reflecting accumulated net losses (e.g., substantial negative retained earnings in 2025 Q3 leading to a smaller positive equity base compared with 2024 periods).
  • Persistent quarterly net losses: 2025 Q4 net income -$32.834 million, with similar negative results in prior quarters (e.g., Q3 -$35.824M, Q2 -$28.654M, Q1 -$43.311M).
  • Ongoing negative cash flow from operating activities: 2025 quarters show net cash from operating activities around -$30 million per quarter (Q2 -$29.95M, Q3 -$33.82M, Q4 -$30.12M; Q1 -$35.90M), indicating continued cash burn from core operations.
  • Leverage remains elevated with around $99 million in long-term debt across 2025 (e.g., Q2 2025 long-term debt $99,279,000; Q3 2025 $99,917,000), which could place pressure on future profitability and interest obligations.
05/24/26 03:46 AM ETAI Generated. May Contain Errors.

Inhibrx Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Inhibrx Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Inhibrx Biosciences' net income appears to be on an upward trend, with a most recent value of -$140.06 million in 2025, falling from -$241.36 million in 2023. The previous period was $1.69 billion in 2024. View Inhibrx Biosciences' forecast to see where analysts expect Inhibrx Biosciences to go next.

Inhibrx Biosciences' total operating income in 2025 was -$135.03 million, based on the following breakdown:
  • Total Gross Profit: $1.30 million
  • Total Operating Expenses: $136.33 million

Over the last 2 years, Inhibrx Biosciences' total revenue changed from $1.80 million in 2023 to $1.30 million in 2025, a change of -27.8%.

Inhibrx Biosciences' total liabilities were at $138.49 million at the end of 2025, a 193.5% increase from 2024, and a 47.6% decrease since 2023.

In the past 2 years, Inhibrx Biosciences' cash and equivalents has ranged from $124.22 million in 2025 to $277.92 million in 2023, and is currently $124.22 million as of their latest financial filing in 2025.

Over the last 2 years, Inhibrx Biosciences' book value per share changed from 3.69 in 2023 to 0.55 in 2025, a change of -85.1%.


Related Companies

Financial statements for NASDAQ:INBX last updated on 5/18/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Your computer is about to become a museum piece
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
You have until June 1
Macroeconomic strategist Dr. Mark Skousen believes June 1 marks a critical turning point for one of the most o...
The Oxford Club | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel